Leqembi为人源化IgG1单克隆抗体,靶向可溶与不可溶的聚集性Aβ蛋白,对原纤维状态Aβ具有高选择性。Leqembi在欧盟和美国的申报均基于一项涉及1795名早期AD患者的大型Ⅲ期临床研究,主要疗效终点为治疗18个月后的临床痴呆评分总和量表(CDR-SB)评分变化,评分越高,病情越严重。结果显示,Leqembi组评分升幅为1.21,安慰剂组为1.66,绝对差值0.45,提示病情进展延缓。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.